Literature DB >> 21993876

Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Masahiro Abe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21993876     DOI： 10.1007/s12185-011-0950-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  18 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 3.  The microenvironment and molecular biology of the multiple myeloma tumor.

Authors:  Miguel Lemaire; Sarah Deleu; Elke De Bruyne; Els Van Valckenborgh; Eline Menu; Karin Vanderkerken
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

4.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Authors:  Annemiek Broyl; Dirk Hose; Henk Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; H Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

Review 5.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

Review 6.  Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Authors:  Antonio Palumbo; Michel Attal; Murielle Roussel
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 7.  Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Authors:  Jacob P Laubach; Robert L Schlossman; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

8.  International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Authors:  Sarah Waheed; John D Shaughnessy; Frits van Rhee; Yazan Alsayed; Bijay Nair; Elias Anaissie; Jackie Szymonifka; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

Review 9.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

Review 10.  Current multiple myeloma treatment strategies with novel agents: a European perspective.

Authors:  Heinz Ludwig; Meral Beksac; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Jean-Luc Harousseau; Urs Hess; Nicolas Ketterer; Martin Kropff; Larisa Mendeleeva; Gareth Morgan; Antonio Palumbo; Torben Plesner; Jesús San Miguel; Ofer Shpilberg; Pia Sondergeld; Pieter Sonneveld; Sonja Zweegman
Journal:  Oncologist       Date:  2010-01-19
View more
  3 in total

1.  Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

Authors:  Daniele Tibullo; Cesarina Giallongo; Fabrizio Puglisi; Daniele Tomassoni; Giuseppina Camiolo; Martina Cristaldi; Maria Violetta Brundo; Carmelina Daniela Anfuso; Gabriella Lupo; Tomaso Stampone; Giovanni Li Volti; Francesco Amenta; Roberto Avola; Vincenzo Bramanti
Journal:  Mol Neurobiol       Date:  2017-05-11       Impact factor: 5.590

Review 2.  The non-canonical functions of the heme oxygenases.

Authors:  Luca Vanella; Ignazio Barbagallo; Daniele Tibullo; Stefano Forte; Agata Zappalà; Giovanni Li Volti
Journal:  Oncotarget       Date:  2016-10-18

3.  Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.

Authors:  Daniele Tibullo; Ignazio Barbagallo; Cesarina Giallongo; Luca Vanella; Concetta Conticello; Alessandra Romano; Salvatore Saccone; Justyna Godos; Francesco Di Raimondo; Giovanni Li Volti
Journal:  Oncotarget       Date:  2016-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.